🏷

Classifications

ICD-O Morphology

Harrison's Part

🔗

Mappings

MONDO

MONDO:0017827 malignant peripheral nerve sheath tumor

Primary MONDO disease identifier for the disease-level MPNST curation entry.

📘

Definitions

1

Pathologic definition of malignant peripheral nerve sheath tumor

MPNST is an uncommon, biologically aggressive soft tissue sarcoma of neural origin that includes NF1-associated, sporadic, and radiation-associated disease.

CASE_DEFINITION General pathologic and clinical definition of malignant peripheral nerve sheath tumor

Show evidence (1 reference)

PMID:24470531 SUPPORT Other

"Malignant peripheral nerve sheath tumors (MPNST) are uncommon, biologically aggressive soft tissue sarcomas of neural origin that pose tremendous challenges to effective therapy."

This review abstract provides a concise disease-level definition of MPNST as an aggressive neural-origin soft tissue sarcoma.

◆

Subtypes

5

predisposition context

NF1-Associated Malignant Peripheral Nerve Sheath Tumor

Predisposition-context facet for tumors arising in the setting of neurofibromatosis type 1, typically after malignant transformation of a pre-existing plexiform neurofibroma.

Show evidence (1 reference)

PMID:24470531 SUPPORT Other

"In 50% of cases, they occur in the context of neurofibromatosis type I, characterized by loss of function mutations to the tumor suppressor neurofibromin; the remainder arise sporadically or following radiation therapy."

This supports NF1-associated MPNST as a major predisposition-context subtype and grounds its relationship to neurofibromin loss.

Sporadic Malignant Peripheral Nerve Sheath Tumor

Predisposition-context facet for tumors arising without recognized NF1 or prior therapeutic radiation.

Show evidence (1 reference)

PMID:24470531 SUPPORT Other

"In 50% of cases, they occur in the context of neurofibromatosis type I, characterized by loss of function mutations to the tumor suppressor neurofibromin; the remainder arise sporadically or following radiation therapy."

This same disease-overview sentence also supports sporadic MPNST as a distinct predisposition-context facet within the parent disease entry.

Radiation-Associated Malignant Peripheral Nerve Sheath Tumor

Predisposition-context facet for tumors arising after prior radiotherapy. This group often shares the conventional PRC2-loss/H3K27me3-loss branch of MPNST biology.

Show evidence (1 reference)

PMID:25240281 SUPPORT Human Clinical

"Malignant peripheral nerve sheath tumors (MPNSTs) represent a group of highly aggressive soft-tissue sarcomas that may occur sporadically, in association with neurofibromatosis type I (NF1 associated) or after radiotherapy."

This genomic study explicitly supports radiation-associated MPNST as a recognized clinical-context subtype within the broader disease.

histological

Epithelioid Malignant Peripheral Nerve Sheath Tumor MONDO:0004540

Histologic facet defined by epithelioid morphology, diffuse S100/SOX10 expression, rare association with NF1, and frequent SMARCB1 loss rather than the typical conventional PRC2-loss pattern.

Show evidence (1 reference)

PMID:25602794 SUPPORT Human Clinical

"Epithelioid malignant peripheral nerve sheath tumor (EMPNST) is rare and differs from conventional malignant peripheral nerve sheath tumor by showing diffuse S-100 protein positivity, infrequent association with NF1, and occasional origin in a schwannoma."

This large clinicopathologic series supports epithelioid MPNST as a distinct histologic facet with characteristic diagnostic features.

Malignant Triton Tumor MONDO:0016757

Histologic facet of MPNST with heterologous rhabdomyoblastic differentiation.

Show evidence (1 reference)

PMID:17149968 SUPPORT Other

"Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation is also known as malignant triton tumor."

This review abstract directly supports malignant triton tumor as a named histologic MPNST subtype.

⚙

Pathophysiology

10

NF1 Biallelic Inactivation

Conventional MPNST evolution commonly begins with complete loss of NF1 tumor suppressor function in Schwann-lineage cells, especially in NF1-associated disease, creating the substrate for additional tumor-suppressor and epigenetic lesions.

Schwann cell CL:0002573

NF1 hgnc:7765

Downstream

Ras Pathway Hyperactivation Loss of neurofibromin removes a major brake on Ras signaling in Schwann-lineage tumor cells.

Show evidence (1 reference)

PMID:36598417 SUPPORT Human Clinical

"Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA)."

This large genomic study explicitly places biallelic NF1 loss upstream of later checkpoint, PRC2, and copy-number events in MPNST evolution.

Ras Pathway Hyperactivation

NF1 loss and additional secondary lesions converge on sustained Ras-pathway signaling, which reinforces malignant growth and cooperates with downstream cell-cycle and chromatin dysregulation.

Schwann cell CL:0002573

Ras protein signal transduction GO:0007265 ↑ INCREASED

Downstream

Cell Cycle Deregulation Persistent Ras signaling contributes to unchecked tumor-cell proliferation.

Show evidence (1 reference)

PMID:29118384 SUPPORT Human Clinical

"Notably, we also identified frequent Ras pathway activating somatic mutations outside of these previously reported recurrently mutated genes."

This genomic study supports convergent activation of the Ras pathway beyond NF1 loss alone in MPNST.

CDKN2A/B Loss

Deletion of CDKN2A/B is an early cooperative event in malignant progression, weakening cell-cycle restraint before or during transition from atypical neurofibroma to overt MPNST.

CDKN2A hgnc:1787 CDKN2B hgnc:1788

cell cycle checkpoint signaling GO:0000075 ↓ DECREASED

Downstream

Cell Cycle Deregulation Loss of CDKN2A/B-mediated checkpoint control permits unchecked cell-cycle entry.

Show evidence (2 references)

PMID:30722027 SUPPORT Human Clinical

"The PN-ANF transition is primarily driven by the deletion of CDKN2A/B."

This genomic progression study supports CDKN2A/B loss as an early checkpoint-disrupting event on the benign-to-malignant path in NF1-associated disease.

PMID:25240281 SUPPORT Human Clinical

"Additionally, we identified frequent somatic alterations of CDKN2A (81% of all MPNSTs) and NF1 (72% of non-NF1-associated MPNSTs), both of which significantly co-occur with PRC2 alterations."

This large genomic cohort confirms that CDKN2A loss is a recurrent event in established MPNSTs across etiologic contexts.

TP53 Pathway Loss

TP53 disruption removes an additional tumor-suppressive barrier, promoting malignant progression and large-scale genomic instability.

TP53 hgnc:11998

DNA damage response GO:0006974 ↓ DECREASED

Downstream

Copy-Number Driven Genomic Instability Loss of TP53-mediated genome surveillance facilitates extensive somatic copy-number aberrations.

Show evidence (1 reference)

PMID:29118384 SUPPORT Human Clinical

"We report recurrent mutations in NF1, SUZ12, EED, TP53 and CDKN2A in our study cohort."

This genomic study confirms TP53 as a recurrent tumor-suppressor lesion in MPNST.

PRC2 Core Complex Inactivation

Conventional MPNSTs recurrently inactivate the PRC2 core components SUZ12 or EED, creating a major epigenetic branch of disease evolution across NF1, sporadic, and radiation-associated settings.

SUZ12 hgnc:17101 EED hgnc:3188

chromatin organization GO:0006325 ⚠ ABNORMAL

Downstream

H3K27 Trimethylation Loss PRC2 loss removes the repressive H3K27me3 chromatin mark.

Show evidence (2 references)

PMID:25240281 SUPPORT Human Clinical

"Using comprehensive genomic approaches, we identified loss-of-function somatic alterations of the Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 92% of sporadic, 70% of NF1-associated and 90% of radiotherapy-associated MPNSTs."

This directly supports recurrent SUZ12/EED loss as a cross-context epigenetic driver in conventional MPNST.

PMID:32642732 SUPPORT Other

"Recent advances in genomic studies identified previously unrecognized critical involvement of polycomb repressor complex 2 (PRC2) core components SUZ12 and EED in transition to malignancy."

This review supports PRC2-core inactivation as a key transition event rather than a late incidental finding.

H3K27 Trimethylation Loss

PRC2-deficient MPNSTs lose global H3K27 trimethylation, producing a diagnostically useful biomarker state and reshaping downstream gene regulation.

regulation of gene expression GO:0010468 ⚠ ABNORMAL

Downstream

Developmental Gene Derepression Loss of H3K27me3 releases normally repressed developmental transcriptional programs.

Show evidence (1 reference)

PMID:25240281 SUPPORT Human Clinical

"MPNSTs with PRC2 loss showed complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3) and aberrant transcriptional activation of multiple PRC2-repressed homeobox master regulators and their regulated developmental pathways."

This directly links PRC2 loss to the characteristic H3K27me3-loss state and its transcriptional consequences.

Developmental Gene Derepression

Loss of PRC2-mediated repression derepresses homeobox and developmental gene programs, reinforcing malignant identity rather than normal Schwann-lineage differentiation.

regulation of gene expression GO:0010468 ⚠ ABNORMAL

Downstream

Cell Cycle Deregulation Aberrant developmental transcription cooperates with checkpoint loss to sustain malignant proliferation.

Show evidence (1 reference)

PMID:25240281 SUPPORT Human Clinical

"MPNSTs with PRC2 loss showed complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3) and aberrant transcriptional activation of multiple PRC2-repressed homeobox master regulators and their regulated developmental pathways."

This supports developmental gene derepression as a specific downstream effect of the PRC2-loss branch.

Copy-Number Driven Genomic Instability

Large-scale somatic copy-number aberrations are a central evolutionary feature of MPNST and help stratify clinically relevant branches of disease.

Show evidence (1 reference)

PMID:36598417 SUPPORT Human Clinical

"Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA)."

This large multiregional genomic study supports copy-number-driven genomic instability as a central consequence of the core MPNST lesion set.

Cell Cycle Deregulation

Multiple upstream lesions converge on unchecked MPNST cell growth, making proliferative drive a final common consequence of the conventional disease program.

Schwann cell CL:0002573

cell population proliferation GO:0008283 ↑ INCREASED

Show evidence (1 reference)

PMID:25240281 SUPPORT In Vitro

"Introduction of the lost PRC2 component in a PRC2-deficient MPNST cell line restored H3K27me3 levels and decreased cell growth."

This cell-line rescue experiment supports proliferation as a downstream phenotype of the PRC2-loss branch.

SMARCB1 Loss in Epithelioid MPNST

Epithelioid MPNST follows a subtype-specific chromatin-disruption branch in which SMARCB1 loss is recurrent, in contrast to the conventional PRC2-loss signature of most non-epithelioid tumors.

SMARCB1 hgnc:11103

chromatin organization GO:0006325 ⚠ ABNORMAL

Show evidence (1 reference)

PMID:30864974 SUPPORT Human Clinical

"Sequencing identified SMARCB1 gene inactivation in 12/16 (75%) EMPNST and all 5 (100%) ESCW through homozygous deletion (N=8), nonsense (N=7), frameshift (N=2), or splice site (N=2) mutations"

This subtype-specific genomic series supports recurrent SMARCB1 inactivation as a key oncogenic event in epithelioid MPNST.

✶

Histopathology

1

Spindle Cell Pattern

Conventional MPNST usually shows a spindle-cell sarcoma pattern rather than overt epithelial or round-cell morphology.

Show evidence (1 reference)

PMID:38954182 SUPPORT Other

"Spindle-cell sarcomas of neural-crest origin, MPNSTs are frequently situated in the extremities and pelvis/trunk, often at the confluence of large nerve roots and bundles."

This review abstract supports spindle-cell morphology as a core histopathologic descriptor of conventional MPNST.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

3

Musculoskeletal 1

Muscle Weakness HP:0001324

Show evidence (1 reference)

PMID:36752552 SUPPORT Human Clinical

"All patients with an MPNST had a tumor >8 cm, motor and sensory deficits, and pain."

This supports motor deficit, represented here with the closest HPO term muscle weakness, as a clinically important manifestation of nerve-involving MPNST.

Constitutional 1

Pain HP:0012531

Show evidence (2 references)

PMID:36752552 SUPPORT Human Clinical

"Malignant peripheral nerve sheath tumors must be suspected in enlarging masses (>5 cm) with the constellation of pain, motor, and sensory deficits."

This supports pain as a common and clinically important MPNST presentation clue.

PMID:16033085 SUPPORT Human Clinical

"MRI was performed on 50 patients with NF1 and nerve sheath tumors, of whom 7 had atypical pain, tumor growth or neurological deficits indicative of malignancy"

In NF1 surveillance, atypical pain is one of the key symptom changes prompting concern for MPNST.

Neoplasm 1

Enlarging Soft Tissue Mass Soft tissue neoplasm HP:0031459

Show evidence (1 reference)

PMID:36752552 SUPPORT Human Clinical

"Malignant peripheral nerve sheath tumors must be suspected in enlarging masses (>5 cm) with the constellation of pain, motor, and sensory deficits."

This clinical series directly supports enlarging mass as a core presenting phenotype of MPNST.

🧬

Genetic Associations

6

NF1 (Germline predisposition with biallelic tumor-suppressor loss)

Gene: NF1 hgnc:7765

Show evidence (1 reference)

PMID:24470531 SUPPORT Other

"In 50% of cases, they occur in the context of neurofibromatosis type I, characterized by loss of function mutations to the tumor suppressor neurofibromin; the remainder arise sporadically or following radiation therapy."

This supports NF1/neurofibromin loss as the defining predisposition lesion in a major subset of MPNST.

CDKN2A (Somatic deletion or loss)

Gene: CDKN2A hgnc:1787

Show evidence (1 reference)

PMID:25240281 SUPPORT Human Clinical

"Additionally, we identified frequent somatic alterations of CDKN2A (81% of all MPNSTs) and NF1 (72% of non-NF1-associated MPNSTs), both of which significantly co-occur with PRC2 alterations."

This large cohort confirms recurrent CDKN2A loss in established MPNST.

TP53 (Somatic loss of function)

Gene: TP53 hgnc:11998

Show evidence (1 reference)

PMID:29118384 SUPPORT Human Clinical

"We report recurrent mutations in NF1, SUZ12, EED, TP53 and CDKN2A in our study cohort."

This genomic study confirms TP53 as a recurrent MPNST driver lesion.

SUZ12 (Somatic PRC2-core loss of function)

Gene: SUZ12 hgnc:17101

Show evidence (1 reference)

PMID:25240281 SUPPORT Human Clinical

"Using comprehensive genomic approaches, we identified loss-of-function somatic alterations of the Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 92% of sporadic, 70% of NF1-associated and 90% of radiotherapy-associated MPNSTs."

This directly supports SUZ12 loss as a recurrent conventional-MPNST driver.

EED (Somatic PRC2-core loss of function)

Gene: EED hgnc:3188

Show evidence (1 reference)

PMID:25240281 SUPPORT Human Clinical

"Using comprehensive genomic approaches, we identified loss-of-function somatic alterations of the Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 92% of sporadic, 70% of NF1-associated and 90% of radiotherapy-associated MPNSTs."

This directly supports EED loss as a recurrent conventional-MPNST driver.

SMARCB1 (Somatic loss of function in epithelioid subtype)

Gene: SMARCB1 hgnc:11103

Show evidence (1 reference)

PMID:30864974 SUPPORT Human Clinical

"Epithelioid malignant peripheral nerve sheath tumors (EMPNST) are characterized by diffuse S-100 and SOX10 positivity, frequent immunohistochemical loss of SMARCB1 expression (70%), and rare association with neurofibromatosis type 1."

This supports SMARCB1 loss as a defining genetic and diagnostic feature of the epithelioid subtype.

💊

Medical Actions

3

Wide Surgical Resection

Action: surgical procedure Ontology label: Surgical Procedure NCIT:C15329

Surgery with negative margins is the chief curative treatment for localized MPNST.

Show evidence (1 reference)

PMID:38954182 SUPPORT Other

"Although surgery with wide excisional margins is now the chief curative approach to localized disease, MPNST-specific survival has not improved in decades."

This review directly supports wide-margin surgery as the chief curative treatment for localized MPNST.

Radiation Therapy

Action: Radiation Therapy NCIT:C15313

Radiotherapy is used for local control, especially in high-grade or margin- threatening disease, although benefit appears context-dependent.

Show evidence (2 references)

PMID:27281262 SUPPORT Human Clinical

"Combination therapy with surgery and RT provides favorable LC."

This single-institution cohort supports radiotherapy as part of local-control management for localized MPNST.

PMID:40795877 SUPPORT Human Clinical

"While RTx did not affect overall survival, it reduced LR risk in sporadic cases"

This multicenter cohort refines radiotherapy use by showing more robust local-control benefit in sporadic disease than in NF1-associated disease.

Ifosfamide-Based Chemotherapy

Action: chemotherapy Ontology label: Chemotherapy NCIT:C15632

Agent: ifosfamide CHEBI:5864

Anthracycline/ifosfamide-based chemotherapy remains a sarcoma-style systemic treatment option for advanced, metastatic, or downstaging settings, but the benefit is still uncertain and no targeted standard of care exists.

Show evidence (2 references)

PMID:38954182 SUPPORT Other

"For advanced and metastatic MPNST, radiation and chemotherapy (chiefly with anthracyclines plus ifosfamide) have somewhat promising but still largely uncertain treatment roles, chiefly in local control, downstaging, and palliation."

This review supports anthracycline/ifosfamide-style chemotherapy as a current but still uncertain systemic option in advanced MPNST.

PMID:28546782 SUPPORT Human Clinical

"Our data suggest that MPNSTs do respond to epirubicin and ifosfamide based chemotherapy and prospective studies are warranted to further define the clinical benefit."

This small retrospective neoadjuvant series provides direct human evidence that ifosfamide/anthracycline-based chemotherapy can induce radiographic response.

🔬

Biochemical Markers

2

H3K27me3 Loss

Show evidence (2 references)

PMID:26645727 SUPPORT Human Clinical

"In contrast, the majority of both sporadic (95%) and radiotherapy-related (91%) MPNSTs showed loss of H3K27me3 expression."

This supports H3K27me3 loss as a practical biomarker for conventional sporadic and radiation-associated MPNST.

PMID:26645727 SUPPORT Human Clinical

"Furthermore, all 5 epithelioid MPNSTs retained H3K27me3 labeling."

This supports retaining epithelioid MPNST as a subtype-specific exception to the conventional PRC2-loss biomarker pattern.

H3K27me2 Loss

Show evidence (1 reference)

PMID:31175328 SUPPORT Human Clinical

"H3K27me2 loss is limited to malignant peripheral nerve sheath tumors and is highly concordant with H3K27me3 loss (33/34 cases)."

This supports H3K27me2 loss as a more specific biomarker for PRC2-deficient MPNST.

📊

Related Datasets

6

Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors geo:GSE303418

Background: Treatment for patients with malignant peripheral nerve sheath tumors (MPNST) is an unmet clinical need. Loss of NF1 in MPNST leads to hyperactivation of RAS oncoproteins, however little is known about relevant downstream oncogenic signaling and effective targeted therapies in MPNST are still lacking. Methods: Conditional gene expression, CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments to explore the effect of reconstituting the GTPase-activating protein-related domain of NF1 or knockdown of A/B/CRAF kinases on ERK signaling output and MPNST cell growth.

human BULK RNA SEQ n=36

PMID:41023593

Identified by GEO DataSets index search for Malignant Peripheral Nerve Sheath Tumor (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Hydroxychloroquine prevents resistance and potentiates antitumor effect of SHP2 inhibition in NF1-associated Malignant Peripheral Nerve Sheath Tumors geo:GSE283902

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within pre-existing benign lesions called plexiform neurofibromas (PNs). PNs are solely driven by biallelic NF1 loss eliciting RAS pathway activation and respond favorably to MEK inhibitor therapy. MPNSTs harbor additional mutations and respond poorly to MEK inhibition. Our analysis of genetically engineered and orthotopic patient-derived xenograft MPNST tumor models indicates that MEK inhibition has poor anti-tumor efficacy.

BULK RNA SEQ n=31

PMID:39793045

Identified by GEO DataSets index search for Malignant Peripheral Nerve Sheath Tumor (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors (RNA-Seq) geo:GSE275048

Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically. While surgery is the primary treatment for localized MPNST with a 61.9% overall survival rate, metastatic disease is often fatal due to resistance to systemic therapies which underscores the urgent need for effective treatments. MPNSTs frequently harbor inactivating driver mutations in the PRC2 epigenetic repressor complex suggesting epigenetic therapies may represent a specific vulnerability in these tumors.

human BULK RNA SEQ n=16

PMID:40128216

Identified by GEO DataSets index search for Malignant Peripheral Nerve Sheath Tumor (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.

Personalised therapy with MEK inhibition leads to a sustained complete response in an adolescent patient with a recurrent malignant peripheral nerve sheath tumor ega:EGAS00001004899

The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal, with surgical resection being the only definitive salvage therapy. Treatment with chemo-radiation approaches has not significantly improved patient outcomes. Similarly, trials of therapies targeting MPNST genomic drivers have thus far been unsuccessful. Improved understanding of the molecular pathogenesis of MPNST indicates frequent activation of the mitogen activated protein kinase (MAPK) cell signaling pathway. MEK inhibitors have shown activity in preclinical studies; however, their clinical efficacy has not been reported to date.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Malignant Peripheral Nerve Sheath Tumor"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma ega:EGAS00001005065

Malignant peripheral nerve sheath tumor (MPNST)-like melanoma is a rare malignancy with overlapping characteristics of both neural sarcoma and melanoma. The genomics of MPNST-like melanoma have not been previously described. This study provides the results of whole exome and transcriptome sequencing analysis of 8 samples from 6 patients with confirmed diagnosis of MPNST-like melanoma. This study demonstrates that MPNST-like melanoma shares oncogenic alterations common to both cutaneous melanoma and MPNST, and also suggests that MPNST-like melanoma harbors unique genomic and transcriptomic alterations.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Malignant Peripheral Nerve Sheath Tumor"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Genomic landscape of malignant peripheral nerve sheath tumor (MPNST) ega:EGAS00001006069

Neurofibromatosis type 1 (NF1) is the most common tumor predisposition syndrome, and is associated with an aggressive soft-tissue sarcoma, malignant peripheral nerve sheath tumours (MPNSTs), the greatest cause of morbidity and mortality in people with NF1. The only potentially curative therapy involves surgery which is not always possible. Even therapy with curative intent is associated with poor overall survival for both sporadic and NF1-related MPNSTs. The development of novel therapies has been largely hindered by a lack of understanding of the molecular events underpinning MPNST pathogenesis.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Malignant Peripheral Nerve Sheath Tumor"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

{ }

Source YAML

click to show

name: Malignant Peripheral Nerve Sheath Tumor
creation_date: '2026-04-12T22:30:00Z'
category: Cancer
categories:
- Sarcoma
- Soft Tissue Sarcoma
- Peripheral Nerve Sheath Tumor
- Rare Cancer
parents:
- soft tissue sarcoma
synonyms:
- MPNST
- malignant schwannoma
- neurofibrosarcoma
- neurogenic sarcoma
disease_term:
  preferred_term: malignant peripheral nerve sheath tumor
  term:
    id: MONDO:0017827
    label: malignant peripheral nerve sheath tumor
description: >-
  Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue
  sarcoma of peripheral nerve sheath lineage. The disease is modeled here as a
  single dismech mechanism-graph unit, with predisposition-context facets
  (NF1-associated, sporadic, radiation-associated) and histologic facets
  (epithelioid, malignant triton tumor) represented as subtype annotations
  rather than separate disease pages. Core conventional MPNST biology converges
  on NF1/RAS pathway activation, loss of CDKN2A and TP53 tumor-suppressor
  checkpoints, recurrent PRC2 inactivation with H3K27me3 loss, and extensive
  copy-number aberrations. Epithelioid MPNST is retained in this entry as a
  subtype-scoped branch because it has distinct SMARCB1-centered biology but
  remains within the broader MPNST disease unit.
definitions:
- name: Pathologic definition of malignant peripheral nerve sheath tumor
  definition_type: CASE_DEFINITION
  description: >-
    MPNST is an uncommon, biologically aggressive soft tissue sarcoma of neural
    origin that includes NF1-associated, sporadic, and radiation-associated
    disease.
  scope: General pathologic and clinical definition of malignant peripheral nerve sheath tumor
  evidence:
  - reference: PMID:24470531
    reference_title: "Malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Malignant peripheral nerve sheath tumors (MPNST) are uncommon, biologically aggressive soft tissue sarcomas of neural origin that pose tremendous challenges to effective therapy."
    explanation: This review abstract provides a concise disease-level definition of MPNST as an aggressive neural-origin soft tissue sarcoma.
has_subtypes:
- name: NF1-Associated
  display_name: NF1-Associated Malignant Peripheral Nerve Sheath Tumor
  classification: predisposition_context
  description: >-
    Predisposition-context facet for tumors arising in the setting of
    neurofibromatosis type 1, typically after malignant transformation of a
    pre-existing plexiform neurofibroma.
  evidence:
  - reference: PMID:24470531
    reference_title: "Malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In 50% of cases, they occur in the context of neurofibromatosis type I, characterized by loss of function mutations to the tumor suppressor neurofibromin; the remainder arise sporadically or following radiation therapy."
    explanation: This supports NF1-associated MPNST as a major predisposition-context subtype and grounds its relationship to neurofibromin loss.
  review_notes: "Flat subtype facet capturing predisposition context rather than a separate dismech disease page, following the cancer-modeling guidance from issue #1198."
- name: Sporadic
  display_name: Sporadic Malignant Peripheral Nerve Sheath Tumor
  classification: predisposition_context
  description: >-
    Predisposition-context facet for tumors arising without recognized NF1 or
    prior therapeutic radiation.
  evidence:
  - reference: PMID:24470531
    reference_title: "Malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In 50% of cases, they occur in the context of neurofibromatosis type I, characterized by loss of function mutations to the tumor suppressor neurofibromin; the remainder arise sporadically or following radiation therapy."
    explanation: This same disease-overview sentence also supports sporadic MPNST as a distinct predisposition-context facet within the parent disease entry.
  review_notes: >-
    Flat subtype facet capturing predisposition context rather than a separate
    disease page.
- name: Radiation-Associated
  display_name: Radiation-Associated Malignant Peripheral Nerve Sheath Tumor
  classification: predisposition_context
  description: >-
    Predisposition-context facet for tumors arising after prior radiotherapy.
    This group often shares the conventional PRC2-loss/H3K27me3-loss branch of
    MPNST biology.
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant peripheral nerve sheath tumors (MPNSTs) represent a group of highly aggressive soft-tissue sarcomas that may occur sporadically, in association with neurofibromatosis type I (NF1 associated) or after radiotherapy."
    explanation: This genomic study explicitly supports radiation-associated MPNST as a recognized clinical-context subtype within the broader disease.
  review_notes: >-
    Flat subtype facet capturing exposure/predisposition context rather than a
    separate disease page.
- name: Epithelioid
  display_name: Epithelioid Malignant Peripheral Nerve Sheath Tumor
  classification: histological
  subtype_term:
    preferred_term: epithelioid malignant peripheral nerve sheath tumor
    term:
      id: MONDO:0004540
      label: epithelioid malignant peripheral nerve sheath tumor
  description: >-
    Histologic facet defined by epithelioid morphology, diffuse S100/SOX10
    expression, rare association with NF1, and frequent SMARCB1 loss rather
    than the typical conventional PRC2-loss pattern.
  evidence:
  - reference: PMID:25602794
    reference_title: "Epithelioid malignant peripheral nerve sheath tumor: clinicopathologic analysis of 63 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epithelioid malignant peripheral nerve sheath tumor (EMPNST) is rare and differs from conventional malignant peripheral nerve sheath tumor by showing diffuse S-100 protein positivity, infrequent association with NF1, and occasional origin in a schwannoma."
    explanation: This large clinicopathologic series supports epithelioid MPNST as a distinct histologic facet with characteristic diagnostic features.
  review_notes: >-
    Represented here as a histologic facet of MPNST rather than a separate
    dismech page; subtype grounding is for ontology alignment only.
- name: Malignant Triton Tumor
  display_name: Malignant Triton Tumor
  classification: histological
  subtype_term:
    preferred_term: malignant triton tumor
    term:
      id: MONDO:0016757
      label: malignant triton tumor
  description: >-
    Histologic facet of MPNST with heterologous rhabdomyoblastic
    differentiation.
  evidence:
  - reference: PMID:17149968
    reference_title: "Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation is also known as malignant triton tumor."
    explanation: This review abstract directly supports malignant triton tumor as a named histologic MPNST subtype.
  review_notes: >-
    Represented as a histologic facet of the parent MPNST entry rather than a
    separate dismech page.
pathophysiology:
- name: NF1 Biallelic Inactivation
  description: >-
    Conventional MPNST evolution commonly begins with complete loss of NF1 tumor
    suppressor function in Schwann-lineage cells, especially in NF1-associated
    disease, creating the substrate for additional tumor-suppressor and
    epigenetic lesions.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF1
    term:
      id: hgnc:7765
      label: NF1
  evidence:
  - reference: PMID:36598417
    reference_title: "Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA)."
    explanation: This large genomic study explicitly places biallelic NF1 loss upstream of later checkpoint, PRC2, and copy-number events in MPNST evolution.
  downstream:
  - target: Ras Pathway Hyperactivation
    description: Loss of neurofibromin removes a major brake on Ras signaling in Schwann-lineage tumor cells.
    evidence:
    - reference: PMID:31023785
      reference_title: "Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Consequently, loss of function mutations in NF1 result in hyperactive Ras signaling, promoting aberrant cellular proliferation."
      explanation: This review directly supports the specific NF1-loss to Ras-hyperactivation mechanism represented by this downstream edge.
- name: Ras Pathway Hyperactivation
  description: >-
    NF1 loss and additional secondary lesions converge on sustained Ras-pathway
    signaling, which reinforces malignant growth and cooperates with downstream
    cell-cycle and chromatin dysregulation.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: Ras protein signal transduction
    modifier: INCREASED
    term:
      id: GO:0007265
      label: Ras protein signal transduction
  evidence:
  - reference: PMID:29118384
    reference_title: "The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, we also identified frequent Ras pathway activating somatic mutations outside of these previously reported recurrently mutated genes."
    explanation: This genomic study supports convergent activation of the Ras pathway beyond NF1 loss alone in MPNST.
  downstream:
  - target: Cell Cycle Deregulation
    description: Persistent Ras signaling contributes to unchecked tumor-cell proliferation.
- name: CDKN2A/B Loss
  description: >-
    Deletion of CDKN2A/B is an early cooperative event in malignant progression,
    weakening cell-cycle restraint before or during transition from atypical
    neurofibroma to overt MPNST.
  genes:
  - preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  - preferred_term: CDKN2B
    term:
      id: hgnc:1788
      label: CDKN2B
  biological_processes:
  - preferred_term: cell cycle checkpoint signaling
    modifier: DECREASED
    term:
      id: GO:0000075
      label: cell cycle checkpoint signaling
  evidence:
  - reference: PMID:30722027
    reference_title: "Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PN-ANF transition is primarily driven by the deletion of CDKN2A/B."
    explanation: This genomic progression study supports CDKN2A/B loss as an early checkpoint-disrupting event on the benign-to-malignant path in NF1-associated disease.
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, we identified frequent somatic alterations of CDKN2A (81% of all MPNSTs) and NF1 (72% of non-NF1-associated MPNSTs), both of which significantly co-occur with PRC2 alterations."
    explanation: This large genomic cohort confirms that CDKN2A loss is a recurrent event in established MPNSTs across etiologic contexts.
  downstream:
  - target: Cell Cycle Deregulation
    description: Loss of CDKN2A/B-mediated checkpoint control permits unchecked cell-cycle entry.
- name: TP53 Pathway Loss
  description: >-
    TP53 disruption removes an additional tumor-suppressive barrier, promoting
    malignant progression and large-scale genomic instability.
  genes:
  - preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  biological_processes:
  - preferred_term: DNA damage response
    modifier: DECREASED
    term:
      id: GO:0006974
      label: DNA damage response
  evidence:
  - reference: PMID:29118384
    reference_title: "The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report recurrent mutations in NF1, SUZ12, EED, TP53 and CDKN2A in our study cohort."
    explanation: This genomic study confirms TP53 as a recurrent tumor-suppressor lesion in MPNST.
  downstream:
  - target: Copy-Number Driven Genomic Instability
    description: Loss of TP53-mediated genome surveillance facilitates extensive somatic copy-number aberrations.
    evidence:
    - reference: PMID:36598417
      reference_title: "Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA)."
      explanation: This supports TP53 loss as one of the major upstream lesions associated with widespread copy-number instability in MPNST.
- name: PRC2 Core Complex Inactivation
  description: >-
    Conventional MPNSTs recurrently inactivate the PRC2 core components SUZ12 or
    EED, creating a major epigenetic branch of disease evolution across NF1,
    sporadic, and radiation-associated settings.
  genes:
  - preferred_term: SUZ12
    term:
      id: hgnc:17101
      label: SUZ12
  - preferred_term: EED
    term:
      id: hgnc:3188
      label: EED
  biological_processes:
  - preferred_term: chromatin organization
    modifier: ABNORMAL
    term:
      id: GO:0006325
      label: chromatin organization
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using comprehensive genomic approaches, we identified loss-of-function somatic alterations of the Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 92% of sporadic, 70% of NF1-associated and 90% of radiotherapy-associated MPNSTs."
    explanation: This directly supports recurrent SUZ12/EED loss as a cross-context epigenetic driver in conventional MPNST.
  - reference: PMID:32642732
    reference_title: "Genetics of human malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Recent advances in genomic studies identified previously unrecognized critical involvement of polycomb repressor complex 2 (PRC2) core components SUZ12 and EED in transition to malignancy."
    explanation: This review supports PRC2-core inactivation as a key transition event rather than a late incidental finding.
  downstream:
  - target: H3K27 Trimethylation Loss
    description: PRC2 loss removes the repressive H3K27me3 chromatin mark.
- name: H3K27 Trimethylation Loss
  description: >-
    PRC2-deficient MPNSTs lose global H3K27 trimethylation, producing a
    diagnostically useful biomarker state and reshaping downstream gene
    regulation.
  biological_processes:
  - preferred_term: regulation of gene expression
    modifier: ABNORMAL
    term:
      id: GO:0010468
      label: regulation of gene expression
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPNSTs with PRC2 loss showed complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3) and aberrant transcriptional activation of multiple PRC2-repressed homeobox master regulators and their regulated developmental pathways."
    explanation: This directly links PRC2 loss to the characteristic H3K27me3-loss state and its transcriptional consequences.
  downstream:
  - target: Developmental Gene Derepression
    description: Loss of H3K27me3 releases normally repressed developmental transcriptional programs.
- name: Developmental Gene Derepression
  description: >-
    Loss of PRC2-mediated repression derepresses homeobox and developmental gene
    programs, reinforcing malignant identity rather than normal Schwann-lineage
    differentiation.
  biological_processes:
  - preferred_term: regulation of gene expression
    modifier: ABNORMAL
    term:
      id: GO:0010468
      label: regulation of gene expression
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MPNSTs with PRC2 loss showed complete loss of trimethylation at lysine 27 of histone H3 (H3K27me3) and aberrant transcriptional activation of multiple PRC2-repressed homeobox master regulators and their regulated developmental pathways."
    explanation: This supports developmental gene derepression as a specific downstream effect of the PRC2-loss branch.
  downstream:
  - target: Cell Cycle Deregulation
    description: Aberrant developmental transcription cooperates with checkpoint loss to sustain malignant proliferation.
- name: Copy-Number Driven Genomic Instability
  description: >-
    Large-scale somatic copy-number aberrations are a central evolutionary
    feature of MPNST and help stratify clinically relevant branches of disease.
  evidence:
  - reference: PMID:36598417
    reference_title: "Genomic Patterns of Malignant Peripheral Nerve Sheath Tumor (MPNST) Evolution Correlate with Clinical Outcome and Are Detectable in Cell-Free DNA."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Following biallelic inactivation of NF1, loss of CDKN2A or TP53 with or without inactivation of polycomb repressive complex 2 (PRC2) leads to extensive somatic copy-number aberrations (SCNA)."
    explanation: This large multiregional genomic study supports copy-number-driven genomic instability as a central consequence of the core MPNST lesion set.
- name: Cell Cycle Deregulation
  description: >-
    Multiple upstream lesions converge on unchecked MPNST cell growth, making
    proliferative drive a final common consequence of the conventional disease
    program.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Introduction of the lost PRC2 component in a PRC2-deficient MPNST cell line restored H3K27me3 levels and decreased cell growth."
    explanation: This cell-line rescue experiment supports proliferation as a downstream phenotype of the PRC2-loss branch.
- name: SMARCB1 Loss in Epithelioid MPNST
  subtypes:
  - Epithelioid
  description: >-
    Epithelioid MPNST follows a subtype-specific chromatin-disruption branch in
    which SMARCB1 loss is recurrent, in contrast to the conventional PRC2-loss
    signature of most non-epithelioid tumors.
  genes:
  - preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  biological_processes:
  - preferred_term: chromatin organization
    modifier: ABNORMAL
    term:
      id: GO:0006325
      label: chromatin organization
  evidence:
  - reference: PMID:30864974
    reference_title: "Recurrent SMARCB1 Inactivation in Epithelioid Malignant Peripheral Nerve Sheath Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sequencing identified SMARCB1 gene inactivation in 12/16 (75%) EMPNST and all 5 (100%) ESCW through homozygous deletion (N=8), nonsense (N=7), frameshift (N=2), or splice site (N=2) mutations"
    explanation: This subtype-specific genomic series supports recurrent SMARCB1 inactivation as a key oncogenic event in epithelioid MPNST.
histopathology:
- name: Spindle Cell Pattern
  finding_term:
    preferred_term: Spindle Cell Pattern
    term:
      id: NCIT:C53643
      label: Spindle Cell Pattern
  description: >-
    Conventional MPNST usually shows a spindle-cell sarcoma pattern rather than
    overt epithelial or round-cell morphology.
  evidence:
  - reference: PMID:38954182
    reference_title: "Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Spindle-cell sarcomas of neural-crest origin, MPNSTs are frequently situated in the extremities and pelvis/trunk, often at the confluence of large nerve roots and bundles."
    explanation: This review abstract supports spindle-cell morphology as a core histopathologic descriptor of conventional MPNST.
phenotypes:
- category: Musculoskeletal
  name: Enlarging Soft Tissue Mass
  diagnostic: true
  description: >-
    Patients commonly present with a progressively enlarging deep soft tissue
    mass, often near a major nerve.
  phenotype_term:
    preferred_term: Soft tissue neoplasm
    term:
      id: HP:0031459
      label: Soft tissue neoplasm
  evidence:
  - reference: PMID:36752552
    reference_title: "Malignant Peripheral Nerve Sheath Tumors of the Brachial Plexus: A Single-Center Experience on Diagnosis, Management, and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant peripheral nerve sheath tumors must be suspected in enlarging masses (>5 cm) with the constellation of pain, motor, and sensory deficits."
    explanation: This clinical series directly supports enlarging mass as a core presenting phenotype of MPNST.
- category: Musculoskeletal
  name: Pain
  description: >-
    Pain is a common presenting symptom and a concerning sign of malignant
    transformation in patients with pre-existing neurofibromas.
  phenotype_term:
    preferred_term: Pain
    term:
      id: HP:0012531
      label: Pain
  evidence:
  - reference: PMID:36752552
    reference_title: "Malignant Peripheral Nerve Sheath Tumors of the Brachial Plexus: A Single-Center Experience on Diagnosis, Management, and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Malignant peripheral nerve sheath tumors must be suspected in enlarging masses (>5 cm) with the constellation of pain, motor, and sensory deficits."
    explanation: This supports pain as a common and clinically important MPNST presentation clue.
  - reference: PMID:16033085
    reference_title: "Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI was performed on 50 patients with NF1 and nerve sheath tumors, of whom 7 had atypical pain, tumor growth or neurological deficits indicative of malignancy"
    explanation: In NF1 surveillance, atypical pain is one of the key symptom changes prompting concern for MPNST.
- category: Neurologic
  name: Muscle Weakness
  description: >-
    Motor deficits may develop when the tumor involves or compresses a major
    nerve plexus or trunk.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
  evidence:
  - reference: PMID:36752552
    reference_title: "Malignant Peripheral Nerve Sheath Tumors of the Brachial Plexus: A Single-Center Experience on Diagnosis, Management, and Outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All patients with an MPNST had a tumor >8 cm, motor and sensory deficits, and pain."
    explanation: This supports motor deficit, represented here with the closest HPO term muscle weakness, as a clinically important manifestation of nerve-involving MPNST.
biochemical:
- name: H3K27me3 Loss
  notes: >-
    Loss of H3K27 trimethylation is a widely used biomarker of conventional
    PRC2-deficient MPNST. Diagnostic performance is strongest in sporadic and
    radiation-associated tumors; epithelioid tumors usually retain H3K27me3.
  evidence:
  - reference: PMID:26645727
    reference_title: "Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In contrast, the majority of both sporadic (95%) and radiotherapy-related (91%) MPNSTs showed loss of H3K27me3 expression."
    explanation: This supports H3K27me3 loss as a practical biomarker for conventional sporadic and radiation-associated MPNST.
  - reference: PMID:26645727
    reference_title: "Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Furthermore, all 5 epithelioid MPNSTs retained H3K27me3 labeling."
    explanation: This supports retaining epithelioid MPNST as a subtype-specific exception to the conventional PRC2-loss biomarker pattern.
- name: H3K27me2 Loss
  notes: >-
    H3K27me2 loss is a more specific biomarker of true PRC2 loss than isolated
    H3K27me3 loss and may sharpen differential diagnosis.
  evidence:
  - reference: PMID:31175328
    reference_title: "Histone H3K27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true PRC2 loss from isolated H3K27 trimethyl loss."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "H3K27me2 loss is limited to malignant peripheral nerve sheath tumors and is highly concordant with H3K27me3 loss (33/34 cases)."
    explanation: This supports H3K27me2 loss as a more specific biomarker for PRC2-deficient MPNST.
genetic:
- name: NF1
  association: Germline predisposition with biallelic tumor-suppressor loss
  gene_term:
    preferred_term: NF1
    term:
      id: hgnc:7765
      label: NF1
  notes: >-
    NF1-associated MPNST typically develops after loss of the remaining wild-type
    NF1 allele in a patient with germline NF1 predisposition.
  evidence:
  - reference: PMID:24470531
    reference_title: "Malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "In 50% of cases, they occur in the context of neurofibromatosis type I, characterized by loss of function mutations to the tumor suppressor neurofibromin; the remainder arise sporadically or following radiation therapy."
    explanation: This supports NF1/neurofibromin loss as the defining predisposition lesion in a major subset of MPNST.
- name: CDKN2A
  association: Somatic deletion or loss
  gene_term:
    preferred_term: CDKN2A
    term:
      id: hgnc:1787
      label: CDKN2A
  notes: >-
    CDKN2A loss is an early and recurrent checkpoint-disrupting event in
    conventional MPNST.
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additionally, we identified frequent somatic alterations of CDKN2A (81% of all MPNSTs) and NF1 (72% of non-NF1-associated MPNSTs), both of which significantly co-occur with PRC2 alterations."
    explanation: This large cohort confirms recurrent CDKN2A loss in established MPNST.
- name: TP53
  association: Somatic loss of function
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  notes: >-
    TP53 loss is a common secondary tumor-suppressor lesion that cooperates with
    NF1 and CDKN2A pathway disruption.
  evidence:
  - reference: PMID:29118384
    reference_title: "The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report recurrent mutations in NF1, SUZ12, EED, TP53 and CDKN2A in our study cohort."
    explanation: This genomic study confirms TP53 as a recurrent MPNST driver lesion.
- name: SUZ12
  association: Somatic PRC2-core loss of function
  gene_term:
    preferred_term: SUZ12
    term:
      id: hgnc:17101
      label: SUZ12
  notes: >-
    SUZ12 is one of the two core PRC2 genes most frequently inactivated in
    conventional MPNST.
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using comprehensive genomic approaches, we identified loss-of-function somatic alterations of the Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 92% of sporadic, 70% of NF1-associated and 90% of radiotherapy-associated MPNSTs."
    explanation: This directly supports SUZ12 loss as a recurrent conventional-MPNST driver.
- name: EED
  association: Somatic PRC2-core loss of function
  gene_term:
    preferred_term: EED
    term:
      id: hgnc:3188
      label: EED
  notes: >-
    EED is the second major recurrent PRC2-core lesion in conventional MPNST.
  evidence:
  - reference: PMID:25240281
    reference_title: "PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Using comprehensive genomic approaches, we identified loss-of-function somatic alterations of the Polycomb repressive complex 2 (PRC2) components (EED or SUZ12) in 92% of sporadic, 70% of NF1-associated and 90% of radiotherapy-associated MPNSTs."
    explanation: This directly supports EED loss as a recurrent conventional-MPNST driver.
- name: SMARCB1
  subtype: Epithelioid
  association: Somatic loss of function in epithelioid subtype
  gene_term:
    preferred_term: SMARCB1
    term:
      id: hgnc:11103
      label: SMARCB1
  notes: >-
    Epithelioid MPNST commonly shows SMARCB1/INI1 loss instead of the canonical
    PRC2-loss signature.
  evidence:
  - reference: PMID:30864974
    reference_title: "Recurrent SMARCB1 Inactivation in Epithelioid Malignant Peripheral Nerve Sheath Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epithelioid malignant peripheral nerve sheath tumors (EMPNST) are characterized by diffuse S-100 and SOX10 positivity, frequent immunohistochemical loss of SMARCB1 expression (70%), and rare association with neurofibromatosis type 1."
    explanation: This supports SMARCB1 loss as a defining genetic and diagnostic feature of the epithelioid subtype.
treatments:
- name: Wide Surgical Resection
  description: >-
    Surgery with negative margins is the chief curative treatment for localized
    MPNST.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  evidence:
  - reference: PMID:38954182
    reference_title: "Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Although surgery with wide excisional margins is now the chief curative approach to localized disease, MPNST-specific survival has not improved in decades."
    explanation: This review directly supports wide-margin surgery as the chief curative treatment for localized MPNST.
- name: Radiation Therapy
  description: >-
    Radiotherapy is used for local control, especially in high-grade or margin-
    threatening disease, although benefit appears context-dependent.
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: Radiation Therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  evidence:
  - reference: PMID:27281262
    reference_title: "Malignant Peripheral Nerve Sheath Tumors: A Single Institution's Experience Using Combined Surgery and Radiation Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Combination therapy with surgery and RT provides favorable LC."
    explanation: This single-institution cohort supports radiotherapy as part of local-control management for localized MPNST.
  - reference: PMID:40795877
    reference_title: "The role of radiotherapy in MPNST and the impact of NF1 status on outcomes: Insights from a multicenter cohort study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "While RTx did not affect overall survival, it reduced LR risk in sporadic cases"
    explanation: This multicenter cohort refines radiotherapy use by showing more robust local-control benefit in sporadic disease than in NF1-associated disease.
- name: Ifosfamide-Based Chemotherapy
  description: >-
    Anthracycline/ifosfamide-based chemotherapy remains a sarcoma-style systemic
    treatment option for advanced, metastatic, or downstaging settings, but the
    benefit is still uncertain and no targeted standard of care exists.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: NCIT:C15632
      label: Chemotherapy
    therapeutic_agent:
    - preferred_term: ifosfamide
      term:
        id: CHEBI:5864
        label: ifosfamide
  evidence:
  - reference: PMID:38954182
    reference_title: "Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "For advanced and metastatic MPNST, radiation and chemotherapy (chiefly with anthracyclines plus ifosfamide) have somewhat promising but still largely uncertain treatment roles, chiefly in local control, downstaging, and palliation."
    explanation: This review supports anthracycline/ifosfamide-style chemotherapy as a current but still uncertain systemic option in advanced MPNST.
  - reference: PMID:28546782
    reference_title: "Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data suggest that MPNSTs do respond to epirubicin and ifosfamide based chemotherapy and prospective studies are warranted to further define the clinical benefit."
    explanation: This small retrospective neoadjuvant series provides direct human evidence that ifosfamide/anthracycline-based chemotherapy can induce radiographic response.
classifications:
  icdo_morphology:
    classification_value: Sarcoma
    evidence:
    - reference: PMID:24470531
      reference_title: "Malignant peripheral nerve sheath tumors."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Malignant peripheral nerve sheath tumors (MPNST) are uncommon, biologically aggressive soft tissue sarcomas of neural origin that pose tremendous challenges to effective therapy."
      explanation: This classifies MPNST as a soft tissue sarcoma.
  harrisons_chapter:
  - classification_value: ONCOLOGY_HEMATOLOGY
    evidence:
    - reference: PMID:38954182
      reference_title: "Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Malignant peripheral sheath tumor (MPNST) is a rare, aggressive form of soft-tissue sarcoma that presents a unique set of diagnostic and treatment challenges and is associated with major unmet treatment medical needs."
      explanation: This supports classification of MPNST as a malignant cancer entity.
    - reference: PMID:24470531
      reference_title: "Malignant peripheral nerve sheath tumors."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "Malignant peripheral nerve sheath tumors (MPNST) are uncommon, biologically aggressive soft tissue sarcomas of neural origin that pose tremendous challenges to effective therapy."
      explanation: This supports classifying MPNST within the solid-tumor sarcoma space.
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0017827
      label: malignant peripheral nerve sheath tumor
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for the disease-level MPNST curation entry.
notes: "Requested NCIT cross-reference: NCIT:C3798. This entry remains MONDO-first at the disease level because the schema currently provides explicit MONDO mapping slots but not structured NCIT disease/subtype mappings. Per cancer curation guidance from #1198, subtype grounding here is used only for facet-style ontology alignment and does not imply separate dismech pages or Not Yet Curated badges."
datasets:
- accession: geo:GSE303418
  title: Selective inhibition of BRAF and CRAF sensitizes NF1-deficient malignant peripheral nerve sheath tumors to MEK inhibitors
  description: 'Background: Treatment for patients with malignant peripheral nerve sheath tumors (MPNST) is an unmet clinical need. Loss of NF1 in MPNST leads to hyperactivation of RAS oncoproteins, however little is known about relevant downstream oncogenic signaling and effective targeted therapies in MPNST are still lacking. Methods: Conditional gene expression, CRISPR-CAS9, and shRNA-mediated knockdown were used to perform gain/loss-of-function experiments to explore the effect of reconstituting the GTPase-activating protein-related domain of NF1 or knockdown of A/B/CRAF kinases on ERK signaling output and MPNST cell growth.'
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 36
  publication: PMID:41023593
  notes: Identified by GEO DataSets index search for Malignant Peripheral Nerve Sheath Tumor (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE283902
  title: Hydroxychloroquine prevents resistance and potentiates antitumor effect of SHP2 inhibition in NF1-associated Malignant Peripheral Nerve Sheath Tumors
  description: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas and the primary cause of mortality in patients with neurofibromatosis type 1 (NF1). These malignancies develop within pre-existing benign lesions called plexiform neurofibromas (PNs). PNs are solely driven by biallelic NF1 loss eliciting RAS pathway activation and respond favorably to MEK inhibitor therapy. MPNSTs harbor additional mutations and respond poorly to MEK inhibition. Our analysis of genetically engineered and orthotopic patient-derived xenograft MPNST tumor models indicates that MEK inhibition has poor anti-tumor efficacy.
  data_type: BULK_RNA_SEQ
  sample_count: 31
  publication: PMID:39793045
  notes: Identified by GEO DataSets index search for Malignant Peripheral Nerve Sheath Tumor (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE275048
  title: The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors (RNA-Seq)
  description: Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically. While surgery is the primary treatment for localized MPNST with a 61.9% overall survival rate, metastatic disease is often fatal due to resistance to systemic therapies which underscores the urgent need for effective treatments. MPNSTs frequently harbor inactivating driver mutations in the PRC2 epigenetic repressor complex suggesting epigenetic therapies may represent a specific vulnerability in these tumors.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 16
  publication: PMID:40128216
  notes: Identified by GEO DataSets index search for Malignant Peripheral Nerve Sheath Tumor (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-08-01. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00001004899
  title: Personalised therapy with MEK inhibition leads to a sustained complete response in an adolescent patient with a recurrent malignant peripheral nerve sheath tumor
  description: The prognosis of recurrent malignant peripheral nerve sheath tumors (MPNST) is dismal, with surgical resection being the only definitive salvage therapy. Treatment with chemo-radiation approaches has not significantly improved patient outcomes. Similarly, trials of therapies targeting MPNST genomic drivers have thus far been unsuccessful. Improved understanding of the molecular pathogenesis of MPNST indicates frequent activation of the mitogen activated protein kinase (MAPK) cell signaling pathway. MEK inhibitors have shown activity in preclinical studies; however, their clinical efficacy has not been reported to date.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Malignant Peripheral Nerve Sheath Tumor"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001005065
  title: Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor-like Melanoma
  description: Malignant peripheral nerve sheath tumor (MPNST)-like melanoma is a rare malignancy with overlapping characteristics of both neural sarcoma and melanoma. The genomics of MPNST-like melanoma have not been previously described. This study provides the results of whole exome and transcriptome sequencing analysis of 8 samples from 6 patients with confirmed diagnosis of MPNST-like melanoma. This study demonstrates that MPNST-like melanoma shares oncogenic alterations common to both cutaneous melanoma and MPNST, and also suggests that MPNST-like melanoma harbors unique genomic and transcriptomic alterations.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Malignant Peripheral Nerve Sheath Tumor"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001006069
  title: Genomic landscape of malignant peripheral nerve sheath tumor (MPNST)
  description: Neurofibromatosis type 1 (NF1) is the most common tumor predisposition syndrome, and is associated with an aggressive soft-tissue sarcoma, malignant peripheral nerve sheath tumours (MPNSTs), the greatest cause of morbidity and mortality in people with NF1. The only potentially curative therapy involves surgery which is not always possible. Even therapy with curative intent is associated with poor overall survival for both sporadic and NF1-related MPNSTs. The development of novel therapies has been largely hindered by a lack of understanding of the molecular events underpinning MPNST pathogenesis.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Malignant Peripheral Nerve Sheath Tumor"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'

📚

References & Deep Research

Deep Research

1

Malignant Peripheral Nerve Sheath Tumor Research Notes ▸

Malignant Peripheral Nerve Sheath Tumor Research Notes

Date: 2026-04-12

Modeling choices

This curation explicitly follows the cancer-modeling guidance called out from dismech issue #1198.

The dismech page is the disease-level mechanism graph for MPNST as a whole, not a page-per-ontology-subclass expansion.
disease_term is MONDO-first: MONDO:0017827 malignant peripheral nerve sheath tumor.
NCIT was handled where the current schema is strongest today: NCIT:C3798 is recorded in the disease-level notes as the requested disease cross-reference, and NCIT histopathology grounding was used for NCIT:C53643 Spindle Cell Pattern.
Subtypes were modeled as flat facet axes, not as separate dismech diseases: predisposition context (NF1-Associated, Sporadic, Radiation-Associated) and histology (Epithelioid, Malignant Triton Tumor).
Epithelioid remained inside the parent MPNST page even though it has a subtype-specific SMARCB1 branch, because the broader disease still shares a common MPNST clinical/pathologic frame and the schema can represent the distinct mechanism with subtype-scoped nodes.

Ontology grounding used

Disease: MONDO:0017827 malignant peripheral nerve sheath tumor
Histologic subtype: MONDO:0004540 epithelioid malignant peripheral nerve sheath tumor
Histologic subtype: MONDO:0016757 malignant triton tumor
Histopathology: NCIT:C53643 Spindle Cell Pattern
Cell type: CL:0002573 Schwann cell
Key GO processes:
GO:0007265 Ras protein signal transduction
GO:0000075 cell cycle checkpoint signaling
GO:0006974 DNA damage response
GO:0006325 chromatin organization
GO:0010468 regulation of gene expression
GO:0008283 cell population proliferation
Phenotypes:
HP:0031459 Soft tissue neoplasm
HP:0012531 Pain
HP:0001324 Muscle weakness
Treatments:
MAXO:0000004 surgical procedure
MAXO:0000014 radiation therapy
MAXO:0000647 chemotherapy
CHEBI:5864 ifosfamide

Core literature used in the YAML

Disease definition and subtype context

PMID:24470531 Farid et al. 2014 review
Used for disease definition, NF1/sporadic/radiation-associated subtype framing, and poor-prognosis treatment context.
Key quote used: "In 50% of cases, they occur in the context of neurofibromatosis type I ... the remainder arise sporadically or following radiation therapy."
PMID:38954182 Somaiah et al. 2024 review
Used for current overview of anatomy, spindle-cell identity, surgical role, and the absence of a targeted standard of care.

Core conventional MPNST mechanism

PMID:36598417 Cortes-Ciriano et al. 2023
Key evolutionary paper for ordering events: NF1 biallelic loss -> CDKN2A/TP53 +/- PRC2 loss -> extensive SCNAs.
Also supports the H3K27me3-loss branch as a distinct evolutionary path.
PMID:29118384 Brohl et al. 2017
Used for recurrent NF1, SUZ12, EED, TP53, and CDKN2A lesions and for convergent Ras-pathway activation.
PMID:30722027 Pemov et al. 2019
Used to keep the progression model atomic: CDKN2A/B deletion is an early step in PN -> atypical neurofibroma transition, whereas PRC2 loss is later.
PMID:25240281 Lee et al. 2014
Key PRC2 paper used for:
- recurrent SUZ12 / EED inactivation across etiologies
- H3K27me3 loss
- homeobox/developmental gene derepression
- cell-growth rescue after PRC2 restoration

Diagnostic biomarker / pathology

PMID:26645727 Prieto-Granada et al. 2016
Used for H3K27me3-loss diagnostic performance and the fact that epithelioid tumors retain H3K27me3.
PMID:31175328 Marchione et al. 2019
Used for the more specific H3K27me2-loss biomarker.

Histologic subtype-specific biology

PMID:25602794 Jo and Fletcher 2015
Used for epithelioid subtype morphology, superficial distribution, diffuse S100 positivity, and infrequent NF1 association.
PMID:30864974 Schaefer et al. 2019
Used for subtype-scoped SMARCB1 inactivation in epithelioid MPNST.
PMID:17149968 Stasik and Tawfik 2006
Used for malignant triton tumor as the rhabdomyoblastic differentiation facet of MPNST.

Clinical phenotype and treatment

PMID:36752552 Donaldson et al. 2023
Used for enlarging mass, pain, and motor/sensory deficit presentation.
PMID:16033085 Friedrich et al. 2005
Used for NF1 surveillance language around atypical pain, tumor growth, and neurologic deficits as malignant-warning features.
PMID:27281262 Bishop et al. 2018
Used for combined surgery plus radiotherapy and local-control outcomes.
PMID:40795877 Jansma et al. 2025
Used to refine radiotherapy interpretation: lower local-recurrence risk in sporadic disease, unclear benefit in NF1-associated disease.
PMID:28546782 Hirbe et al. 2017
Used for direct human evidence that ifosfamide/anthracycline-based chemotherapy can induce response.

Curation-specific decisions

I did not split epithelioid MPNST into its own disease file even though it has a distinct SMARCB1 branch. Under the #1198 rule set, that would only be warranted if it needed a genuinely separate disease-level mechanism graph. Here, subtype-scoped mechanism and genetic nodes are sufficient.
I did not create separate files for NF1-associated or radiation-associated MPNST. Those are important subtype facets, but they still sit inside the same parent MPNST mechanism graph.
I kept the conventional pathophysiology nodes atomic: NF1 Biallelic Inactivation, Ras Pathway Hyperactivation, CDKN2A/B Loss, TP53 Pathway Loss, PRC2 Core Complex Inactivation, H3K27 Trimethylation Loss, Developmental Gene Derepression, and Copy-Number Driven Genomic Instability.

Malignant Peripheral Nerve Sheath Tumor

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Subtypes

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Related Datasets

Source YAML

References & Deep Research

Deep Research

Malignant Peripheral Nerve Sheath Tumor Research Notes

Modeling choices

Ontology grounding used

Core literature used in the YAML

Disease definition and subtype context

Core conventional MPNST mechanism

Diagnostic biomarker / pathology

Histologic subtype-specific biology

Clinical phenotype and treatment

Curation-specific decisions